Are you working on cases related to the adverse gastrointestinal effects of Ozempic® & Wegovy®?
Contact us to find out how Expert Institute can assist you in building a stronger case.
Fill out this form to get started
Semaglutide, sold under the brand names Ozempic® and Wegovy®, is a GLP-1 receptor agonist used for diabetes management and weight loss. Recent findings suggest a potential link between this drug and gastroparesis, which affects stomach emptying. The Obesity Medicine Association has highlighted the possible effects of GLP-1RA medications on gastric motility.
Despite this, these drugs have been extensively marketed to the public, and the medical community as a safe, and effective treatment option. This raises an important issue: were the potential risks of gastroparesis sufficiently communicated to the countless individuals who placed their trust in its benefits?
Optimize firm performance throughout the entire case lifecycle.
Research Guides
Dive into litigation research that bolsters your legal theory and highlights prevailing counterarguments, ensuring you're primed to address the most pivotal questions, whether at deposition or trial.
Medical Chronologies
Enhance your understanding of a client's medical history with smart, digitized, hyperlinked, and searchable medical chronologies.
Medical Record Reviews
Our physicians can review medical records to determine whether your client's gastrointestinal issues are due to their reliance on Ozempic® or similar drugs.
Expert Search
We’ll help you retain an industry-leading expert specializing in Endocrinology, Gastroenterology, FDA Regulations and more.
Expert Radar
Know everything about defense experts, and your own experts, including all of their litigation history, Daubert challenges, deposition / trial transcripts, malpractice claims, board sanctions, and more.
Mass Tort Accelerator
Access a suite of case evaluation tools designed to refine your mass tort intake strategy and equip you to handle complex litigation effectively.